###begin article-title 0
###xml 80 82 80 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 53 57 <span type="species:ncbi:10116">rats</span>
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
###end article-title 0
###begin title 1
Rationale
###end title 1
###begin p 2
###xml 32 34 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 255 257 255 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 414 416 414 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 111 117 <span type="species:ncbi:9606">humans</span>
###xml 217 223 <span type="species:ncbi:9606">humans</span>
###xml 430 434 <span type="species:ncbi:10116">rats</span>
Compounds that activate the 5-HT2A receptor, such as lysergic acid diethylamide (LSD), act as hallucinogens in humans. One notable exception is the LSD congener lisuride, which does not have hallucinogenic effects in humans even though it is a potent 5-HT2A agonist. LSD and other hallucinogens have been shown to disrupt prepulse inhibition (PPI), an operational measure of sensorimotor gating, by activating 5-HT2A receptors in rats.
###end p 2
###begin title 3
Objective
###end title 3
###begin p 4
###xml 48 67 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
We tested whether lisuride disrupts PPI in male Sprague-Dawley rats. Experiments were also conducted to identify the mechanism(s) responsible for the effect of lisuride on PPI and to compare the effects of lisuride to those of LSD.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 153 155 153 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 393 395 393 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 481 482 481 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 484 485 484 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Confirming a previous report, LSD (0.05, 0.1, and 0.2 mg/kg, s.c.) reduced PPI, and the effect of LSD was blocked by pretreatment with the selective 5-HT2A antagonist MDL 11,939. Administration of lisuride (0.0375, 0.075, and 0.15 mg/kg, s.c.) also reduced PPI. However, the PPI disruption induced by lisuride (0.075 mg/kg) was not blocked by pretreatment with MDL 11,939 or the selective 5-HT1A antagonist WAY-100635 but was prevented by pretreatment with the selective dopamine D2/D3 receptor antagonist raclopride (0.1 mg/kg, s.c).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 91 93 91 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 355 357 355 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
The effect of LSD on PPI is mediated by the 5-HT2A receptor, whereas activation of the 5-HT2A receptor does not appear to contribute to the effect of lisuride on PPI. These findings demonstrate that lisuride and LSD disrupt PPI via distinct receptor mechanisms and provide additional support for the classification of lisuride as a non-hallucinogenic 5-HT2A agonist.
###end p 8
###begin title 9
Keywords
###end title 9
###begin p 10
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 82 86 82 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11</sub>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 359 361 359 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1990</xref>
###xml 599 601 599 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1984</xref>
###xml 656 660 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR66">1988</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">1989</xref>
###xml 801 803 801 803 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR59">1994</xref>
###xml 863 868 863 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR62">1995a</xref>
###xml 891 895 891 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">1998</xref>
###xml 912 916 912 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR70">2001</xref>
###xml 1107 1109 1107 1109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1151 1155 1151 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 1176 1180 1176 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">2009</xref>
###xml 1201 1202 1201 1202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1328 1332 1328 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR71">1998</xref>
###xml 1385 1387 1385 1387 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1488 1490 1488 1490 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1629 1633 1629 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 495 501 <span type="species:ncbi:9606">humans</span>
###xml 694 698 <span type="species:ncbi:10116">rats</span>
###xml 1123 1127 <span type="species:ncbi:10090">mice</span>
###xml 1292 1297 <span type="species:ncbi:9606">human</span>
Considerable evidence demonstrates that the 5-HT2A receptor, which is coupled to Gq/11 and activates the phosphoinositide (PI) signaling pathway (Nichols and Nichols 2008), is largely responsible for mediating the effects of lysergic acid diethylamide (LSD) and other serotonergic hallucinogens. Phenylalkylamine and indoleamine hallucinogens bind to the 5-HT2A receptor with high affinity and act as agonists or partial agonists (Glennon 1990). It has been shown that hallucinogenic potency in humans and behavioral activity in laboratory animals are robustly and significantly correlated with 5-HT2A binding affinity (Glennon et al. 1984; Titeler et al. 1988; Sadzot et al. 1989). Studies in rats have consistently found that the behavioral effects of hallucinogens are blocked by the selective 5-HT2A antagonist M100907 (Schreiber et al. 1994; Sipes and Geyer 1995a; Krebs-Thomson et al. 1998; Vickers et al. 2001). Likewise, the ability of the hallucinogen 2,5-dimethoxy-4-iodoamphetamine (DOI) to induce head twitch response (HTR) and ear scratch and to increase locomotor activity is abolished in 5-HT2A -/- knockout mice (Gonzalez-Maeso et al. 2007; Halberstadt et al. 2009). The selective 5-HT2 antagonist ketanserin blocks the hallucinogenic effects of the indoleamine psilocybin in human subjects (Vollenweider et al. 1998), providing strong support for the link between 5-HT2A receptor activation and hallucinogenesis. Such evidence has implications for the involvement of 5-HT2A receptor activation in the symptoms of schizophrenia and the mechanisms of action of atypical antipsychotic drugs (Geyer and Vollenweider 2008).
###end p 10
###begin p 11
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">1977</xref>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR64">1978</xref>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">1983</xref>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">1978</xref>
###xml 283 287 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">1980</xref>
###xml 329 333 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">1981</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">1983</xref>
###xml 568 572 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">1989</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">1996</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1998</xref>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2002</xref>
###xml 655 659 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2002</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2002</xref>
###xml 744 746 744 746 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 813 817 813 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1998</xref>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2003</xref>
###xml 863 867 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2008</xref>
###xml 1073 1077 1072 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">1977</xref>
###xml 1092 1096 1091 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">1980</xref>
###xml 1115 1119 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">1983</xref>
###xml 1134 1138 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2006</xref>
###xml 1282 1286 1280 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR65">1949</xref>
###xml 1303 1307 1301 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">1958</xref>
###xml 1017 1023 <span type="species:ncbi:9606">humans</span>
Lisuride hydrogen maleate is an isolysergic acid derivative that has been used clinically in the treatment of migraine (Herrmann et al. 1977; Somerville and Herrmann 1978), cluster headache (Raffaelli et al. 1983), acromegaly and hyperprolactinemia (Liuzzi et al. 1978; Verde et al. 1980), and Parkinson's disease (Parkes et al. 1981; Lieberman et al. 1983). The structure and pharmacological activity of lisuride are strikingly similar to that of LSD. Lisuride and LSD bind non-selectively to a variety of serotonergic, dopaminergic, and adrenergic receptors (Leysen 1989; Piercey et al. 1996; Egan et al. 1998; Marona-Lewicka et al. 2002; Millan et al. 2002; Nichols et al. 2002). Furthermore, LSD and lisuride have high affinity for the 5-HT2A receptor, and both compounds act as partial agonists (Egan et al. 1998; Kurrasch-Orbaugh et al. 2003; Cussac et al. 2008). Nonetheless, despite the similar pharmacological properties of lisuride and LSD, lisuride is devoid of hallucinogenic effects when administered to humans at acute doses of up to 400 mug (Herrmann et al. 1977; Verde et al. 1980; Raffaelli et al. 1983; Benes et al. 2006). This lack of effect contrasts with the potent hallucinogenic activity of LSD, which is psychoactive even at doses as low as 20-30 mug (Stoll 1949; Greiner et al. 1958).
###end p 11
###begin p 12
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">1977</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">1981</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR77">1981</xref>
###xml 846 848 846 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 875 879 875 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1984</xref>
###xml 897 902 897 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1995a</xref>
###xml 1182 1186 1182 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR74">1982</xref>
###xml 1206 1210 1206 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">1985</xref>
###xml 1228 1233 1228 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1995b</xref>
###xml 1306 1310 1306 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1982</xref>
###xml 1334 1338 1334 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2002</xref>
###xml 1498 1502 1498 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1985</xref>
###xml 463 467 <span type="species:ncbi:9685">cats</span>
Given the fact that lisuride is not hallucinogenic, many studies have compared the effects of LSD and lisuride directly in order to detect neurochemical differences that may explain why the latter drug is inactive. Toward this goal, lisuride has been tested in several animal behavioral paradigms known to be sensitive to the effects of hallucinogens. Jacobs et al. (1977) proposed that the ability of hallucinogens to induce limb flicks and abortive grooming in cats serves as an animal model of hallucinogen effects. However, lisuride also induces limb flicking and abortive grooming (Marini et al. 1981; White et al. 1981), and thus, this model cannot distinguish between LSD and lisuride. Drug discrimination studies have evaluated whether lisuride can evoke a hallucinogen-like discriminative stimulus, an effect known to be mediated by 5-HT2A receptors (Glennon et al. 1984; Fiorella et al. 1995a). There is some disagreement in the literature regarding the degree to which the stimulus effects of LSD, DOI, and 2,5-dimethoxy-4-methylamphetamine (DOM) generalize to lisuride, with some studies reporting full substitution of lisuride for those training drugs (White and Appel 1982; Glennon and Hauck 1985; Fiorella et al. 1995b) and other studies reporting only partial substitution (Holohean et al. 1982; Marona-Lewicka et al. 2002); nonetheless, it is clear that at least some similarity exists between the interoceptive stimulus cues evoked by hallucinogens and lisuride. Adams and Geyer (1985) compared the effects of lisuride and LSD on investigatory behavior and patterns of locomotor activity. The locomotor effects produced by lisuride were found to be distinct from those of LSD and closely resembled the effects of the dopamine (DA) agonist apomorphine.
###end p 12
###begin p 13
###xml 125 127 125 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">1995</xref>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR70">2001</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 261 263 261 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">1985</xref>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 566 568 566 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1250 1254 1250 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR61">1994</xref>
###xml 1273 1277 1273 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">1995</xref>
###xml 1296 1300 1296 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2001</xref>
###xml 1337 1341 1337 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR72">2007</xref>
###xml 1442 1444 1442 1444 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1473 1477 1473 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2001</xref>
###xml 62 66 <span type="species:ncbi:10116">rats</span>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 740 745 <span type="species:ncbi:9606">human</span>
###xml 966 972 <span type="species:ncbi:9606">humans</span>
###xml 1309 1315 <span type="species:ncbi:9606">humans</span>
###xml 1418 1422 <span type="species:ncbi:10116">rats</span>
###xml 1555 1559 <span type="species:ncbi:10116">rats</span>
Hallucinogens, including LSD, DOI, and DOM, induce the HTR in rats and mice, an effect that is mediated by activation of 5-HT2A receptors (Schreiber et al. 1995; Vickers et al. 2001; Gonzalez-Maeso et al. 2007). Notably, despite the fact that lisuride is a 5-HT2A agonist, studies indicate that lisuride does not evoke the HTR (Gerber et al. 1985; Gonzalez-Maeso et al. 2007). Based on the behavioral inactivity of lisuride in this paradigm, it appears that the HTR has utility as a behavioral screen that can distinguish hallucinogenic versus nonhallucinogenic 5-HT2A agonists. Unfortunately, the usefulness of the HTR as tool to study the effects of hallucinogens is diminished by the fact that the HTR is a behavioral effect that has no human counterpart, and thus, it is unclear how this behavior relates to the subjective effects of hallucinogens. By contrast, prepulse inhibition (PPI) of acoustic startle is a cross-species phenomenon that can be assessed in humans and animals using similar testing procedures. PPI refers to the fact that a weak prestimulus will attenuate the reaction to a subsequent startle-inducing stimulus and serves as an operational measure of sensorimotor gating. Hallucinogens affect PPI in rodents (Sipes and Geyer 1994; Johansson et al. 1995; Ouagazzal et al. 2001) and in humans (Vollenweider et al. 2007). Importantly, it has been shown that the decrease in PPI induced by LSD in rats is mediated by 5-HT2A receptors (Ouagazzal et al. 2001). The present studies were designed to test whether lisuride disrupts PPI in rats. Experiments were also conducted to identify the mechanism(s) responsible for the effect of lisuride on PPI and to compare the effects of lisuride to those of LSD.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
Animals
###end title 15
###begin p 16
###xml 5 24 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
Male Sprague-Dawley rats (Harlan Industries, Indianapolis, IN, USA; initial weight 250-275 g) were housed in pairs in a temperature- and humidity-controlled vivarium under a 12-h reverse light-dark cycle (lights off at 0700 hours). Food and water were available ad libitum. Animals were acclimatized for approximately 1 week after arrival prior to behavioral testing and maintained in American Association for Accreditation of Laboratory Animal Care-approved facilities that meet all federal and state guidelines. Procedures were approved by the University of California San Diego institutional animal care and use committee. Principles of laboratory animal care were followed as well as specific laws of the USA.
###end p 16
###begin title 17
Apparatus
###end title 17
###begin p 18
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">1988</xref>
###xml 905 909 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">1988</xref>
###xml 682 685 <span type="species:ncbi:10116">rat</span>
Eight startle chambers (SR-LAB system, San Diego Instruments, San Diego, CA) were used to measure startle reactivity (Mansbach et al. 1988). The startle test chambers consist of a sound-attenuated, lighted, and ventilated enclosure holding a clear nonrestrictive cylindrical Plexiglas stabilimeter, 8.2 cm in diameter. A high-frequency loudspeaker mounted 24 cm above the Plexiglas cylinder produced all acoustic stimuli. The peak and average amplitudes of the startle response were detected by a piezoelectric accelerometer, digitized, and stored on disk. At the onset of the startling stimulus, 100 1-ms readings were recorded, and the average amplitude was used to determine the rat startle response. A dynamic calibration system was used to ensure comparable stabilimeter sensitivity across test chambers, and sound levels were measured using the dB(A) scale, as described previously (Mansbach et al. 1988).
###end p 18
###begin title 19
Acoustic startle sessions
###end title 19
###begin p 20
###xml 451 455 <span type="species:ncbi:10116">rats</span>
Acoustic startle test sessions consisted of startle trials (pulse-alone) and prepulse trials (prepulse + pulse). The pulse-alone trial consisted of a 40-ms 120-dB pulse of broadband white noise. Prepulse + pulse trials consisted of a 20-ms acoustic prepulse, an 80-ms delay, and then a 40-ms 120-dB startle pulse (100 ms onset-onset). There was an average of 15 s (range, 9-21 s) between trials. During each inter-trial interval, the movements of the rats were recorded once to measure responding when no stimulus was present (data not shown). Each startle session began with a 5-min acclimation period to a 65-dB broadband noise that was present continuously throughout the session. One week after arrival, animals were tested in a brief baseline startle/PPI session to create treatment groups matched for levels of startle and PPI.
###end p 20
###begin p 21
For experiments with lisuride, the startle test session included three blocks. The first block tested acoustic startle response only and included four each of five different acoustic stimulus intensities: 80, 90, 100, 110, and 120 dB (unpublished data). The second block was designed to assess PPI; it contained 12 pulse-alone trials and 30 prepulse + pulse trials [ten prepulses each of 68, 71, and 77 dB (or 3, 6, and 12 dB above background)] presented in a pseudo-randomized order. The third block tested the effect of varying the inter-trial interval on PPI (unpublished data); it contained eight pulse-alone trials and 20 prepulse + pulse trials [77 dB prepulses (12 dB above background)]. Five inter-trial intervals (onset-onset) were used for the prepulse + pulse trials: 30, 60, 120, 240, or 2,000 ms. Five pulse-alone trials were presented at the beginning and the end of the test session but were not used in the calculation of PPI values.
###end p 21
###begin p 22
For experiments with LSD, the startle test session included only one block. The test session contained 14 pulse-alone trials and 36 prepulse + pulse trials [12 prepulses each of 68, 71, and 77 dB (or 3, 6, and 12 dB above background)] presented in a pseudo-randomized order. Five pulse-alone trials were presented at the beginning and the end of the test session but were not used in the calculation of PPI values.
###end p 22
###begin title 23
Data analysis
###end title 23
###begin p 24
The amount of PPI was calculated as a percentage score for each prepulse + pulse trial type:%PPI = 100- {[(startle response for prepulse + pulse trial)/(startle response for pulse-alone trial)] x 100}. Startle magnitude was calculated as the average response to all of the pulse-alone trials. PPI data were analyzed with two- or three-factor analysis of variance (ANOVA) with pretreatment and/or treatment as between-subjects factors and trial type (prepulse intensity) as a repeated measure. For experiments in which there was no significant interaction between drug and prepulse intensity, PPI data were collapsed across prepulse intensity and the average PPI was used as the main dependent measure. Startle magnitude data were analyzed with one- or two-factor (pretreatment and/or treatment) ANOVA. Post-hoc analyses were carried out using Tukey's test. The alpha level was set at 0.05.
###end p 24
###begin title 25
Experimental design
###end title 25
###begin p 26
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 246 247 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 410 411 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 574 575 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 738 739 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 840 841 820 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 133 137 <span type="species:ncbi:10116">rats</span>
###xml 240 244 <span type="species:ncbi:10116">rats</span>
###xml 404 408 <span type="species:ncbi:10116">rats</span>
###xml 568 572 <span type="species:ncbi:10116">rats</span>
###xml 732 736 <span type="species:ncbi:10116">rats</span>
###xml 834 838 <span type="species:ncbi:10116">rats</span>
Animals were placed in the startle chambers 10 min after treatment with lisuride or 5 min after treatment with LSD. In experiment 1, rats (n = 9-10, 38 total) were treated with vehicle, 37.5, 75, or 150 microg/kg lisuride. In experiment 2, rats (n = 10-12, 45 total) were treated with MDL 11,939 (vehicle or 0.3 mg/kg) 20 min before administration of lisuride (vehicle or 75 microg/kg). In experiment 3, rats (n = 11-12, 46 total) were treated with raclopride (vehicle or 0.1 mg/kg) 10 min before administration of lisuride (vehicle or 75 microg/kg). In experiment 4, rats (n = 12-13, 50 total) were treated with WAY-100635 (vehicle or 1.0 mg/kg) 20 min before administration of lisuride (vehicle or 75 microg/kg). In experiment 5, rats (n = 11-12, 47 total) were treated with vehicle, 50, 100, or 200 microg/kg LSD. In experiment 6, rats (n = 11-12, 46 total) were treated with MDL 11,939 (vehicle or 0.3 mg/kg) 25 min before administration of LSD (vehicle or 100 microg/kg).
###end p 26
###begin title 27
Drugs
###end title 27
###begin p 28
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Drugs used were as follows: lisuride hydrogen maleate (purity 98.9%, IVAX Pharmaceuticals, Opava, Czech Republic); S-(-)-raclopride tartrate, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate (WAY-100635; Sigma-Aldrich, St. Louis, MO, USA); alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol (MDL 11,939; Tocris Bioscience, Ellisville, MO, USA); and (+)-lysergic acid diethylamide tartrate (LSD) (National Institute on Drug Abuse, Rockville, MD, USA). Drug doses are expressed as the salt form of the drug, with the exception of MDL 11,939, which refers to the freebase. Lisuride and LSD were dissolved in nitrogen-purged isotonic saline. MDL 11,939 was dissolved in saline (pH 5.0) containing 0.75% Tween 80. All other drugs were dissolved in isotonic saline. All drugs were administered subcutaneously in the nape of the neck in a volume of 1 ml/kg.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Experiment 1: lisuride dose response
###end title 30
###begin p 31
###xml 17 18 17 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 91 92 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 275 276 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 441 442 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 608 609 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 731 732 723 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 888 889 876 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 999 1000 983 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1079 1080 1063 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1095 1096 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1208 1209 1188 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1224 1225 1204 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1587 1588 1557 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1603 1604 1573 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1653 1654 1623 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1669 1670 1639 1640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1680 1686 1650 1656 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1686 1696 1656 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 1779 1790 1749 1760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 1948 1949 1916 1917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1960 1961 1928 1929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1686 2014 1656 1982 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><italic>Left panel</italic> Effects of lisuride (0.0375, 0.075, and 0.15&#160;mg/kg, s.c.) on prepulse inhibition. <italic>Right panel</italic> Effects of lisuride averaged across the three prepulse intensities. Values represent mean &#177; SEM for each group. Drug doses are in milligram per kilogram. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control</p>
###xml 1686 2014 1656 1982 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><italic>Left panel</italic> Effects of lisuride (0.0375, 0.075, and 0.15&#160;mg/kg, s.c.) on prepulse inhibition. <italic>Right panel</italic> Effects of lisuride averaged across the three prepulse intensities. Values represent mean &#177; SEM for each group. Drug doses are in milligram per kilogram. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control</p></caption>
###xml 2014 2014 1982 1982 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="213_2009_1718_Fig1_HTML" id="MO1"/>
###xml 1680 2014 1650 1982 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="32"><italic>Left panel</italic> Effects of lisuride (0.0375, 0.075, and 0.15&#160;mg/kg, s.c.) on prepulse inhibition. <italic>Right panel</italic> Effects of lisuride averaged across the three prepulse intensities. Values represent mean &#177; SEM for each group. Drug doses are in milligram per kilogram. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control</p></caption><graphic position="anchor" xlink:href="213_2009_1718_Fig1_HTML" id="MO1"/></fig>
###xml 2014 2021 1982 1989 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 2021 2066 1989 2034 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Effect of drug treatment on startle magnitude</p>
###xml 2021 2066 1989 2034 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Effect of drug treatment on startle magnitude</p></caption>
###xml 2066 2086 2034 2054 <th xmlns:xlink="http://www.w3.org/1999/xlink">Pretreatment (mg/kg)</th>
###xml 2086 2103 2054 2071 <th xmlns:xlink="http://www.w3.org/1999/xlink">Treatment (mg/kg)</th>
###xml 2103 2104 2071 2072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2103 2104 2071 2072 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic></th>
###xml 2104 2136 2072 2102 <th xmlns:xlink="http://www.w3.org/1999/xlink">Startle magnitude (mean &#177; SEM)</th>
###xml 2066 2136 2034 2102 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Pretreatment (mg/kg)</th><th>Treatment (mg/kg)</th><th><italic>n</italic></th><th>Startle magnitude (mean &#177; SEM)</th></tr>
###xml 2066 2136 2034 2102 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Pretreatment (mg/kg)</th><th>Treatment (mg/kg)</th><th><italic>n</italic></th><th>Startle magnitude (mean &#177; SEM)</th></tr></thead>
###xml 2136 2136 2102 2102 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4"/>
###xml 2136 2143 2102 2109 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2143 2144 2109 2110 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 2144 2160 2110 2124 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">457.95&#8201;&#177;&#8201;67.80</td>
###xml 2136 2160 2102 2124 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4"/><td>Vehicle</td><td char="." align="char">9</td><td char="&#177;" align="char">457.95&#8201;&#177;&#8201;67.80</td></tr>
###xml 2160 2175 2124 2139 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.0375</td>
###xml 2175 2177 2139 2141 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 2177 2194 2141 2156 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">221.68&#8201;&#177;&#8201;45.98*</td>
###xml 2160 2194 2124 2156 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Lisuride 0.0375</td><td char="." align="char">10</td><td char="&#177;" align="char">221.68&#8201;&#177;&#8201;45.98*</td></tr>
###xml 2194 2208 2156 2170 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.075</td>
###xml 2208 2210 2170 2172 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 2210 2226 2172 2186 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">247.43&#8201;&#177;&#8201;36.41</td>
###xml 2194 2226 2156 2186 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">247.43&#8201;&#177;&#8201;36.41</td></tr>
###xml 2226 2239 2186 2199 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.15</td>
###xml 2239 2240 2199 2200 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 2240 2256 2200 2214 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">389.55&#8201;&#177;&#8201;69.80</td>
###xml 2226 2256 2186 2214 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Lisuride 0.15</td><td char="." align="char">9</td><td char="&#177;" align="char">389.55&#8201;&#177;&#8201;69.80</td></tr>
###xml 2256 2263 2214 2221 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2263 2270 2221 2228 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2270 2272 2228 2230 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 2272 2288 2230 2244 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">275.30&#8201;&#177;&#8201;36.60</td>
###xml 2256 2288 2214 2244 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">275.30&#8201;&#177;&#8201;36.60</td></tr>
###xml 2288 2302 2244 2258 <td xmlns:xlink="http://www.w3.org/1999/xlink">MDL 11,939 0.3</td>
###xml 2302 2309 2258 2265 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2309 2311 2265 2267 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2311 2327 2267 2281 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">300.94&#8201;&#177;&#8201;44.15</td>
###xml 2288 2327 2244 2281 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">300.94&#8201;&#177;&#8201;44.15</td></tr>
###xml 2327 2334 2281 2288 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2334 2348 2288 2302 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.075</td>
###xml 2348 2350 2302 2304 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 2350 2366 2304 2318 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">178.96&#8201;&#177;&#8201;30.63</td>
###xml 2327 2366 2281 2318 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">178.96&#8201;&#177;&#8201;30.63</td></tr>
###xml 2366 2380 2318 2332 <td xmlns:xlink="http://www.w3.org/1999/xlink">MDL 11,939 0.3</td>
###xml 2380 2394 2332 2346 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.075</td>
###xml 2394 2396 2346 2348 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2396 2412 2348 2362 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">202.83&#8201;&#177;&#8201;29.89</td>
###xml 2366 2412 2318 2362 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>MDL 11,939 0.3</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">202.83&#8201;&#177;&#8201;29.89</td></tr>
###xml 2412 2419 2362 2369 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2419 2426 2369 2376 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2426 2428 2376 2378 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2428 2444 2378 2392 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">437.63&#8201;&#177;&#8201;83.94</td>
###xml 2412 2444 2362 2392 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">437.63&#8201;&#177;&#8201;83.94</td></tr>
###xml 2444 2458 2392 2406 <td xmlns:xlink="http://www.w3.org/1999/xlink">Raclopride 0.1</td>
###xml 2458 2465 2406 2413 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2465 2467 2413 2415 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 2467 2483 2415 2429 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">260.07&#8201;&#177;&#8201;29.69</td>
###xml 2444 2483 2392 2429 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Raclopride 0.1</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">260.07&#8201;&#177;&#8201;29.69</td></tr>
###xml 2483 2490 2429 2436 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2490 2504 2436 2450 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.075</td>
###xml 2504 2506 2450 2452 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 2506 2522 2452 2466 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">262.48&#8201;&#177;&#8201;53.36</td>
###xml 2483 2522 2429 2466 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">11</td><td char="&#177;" align="char">262.48&#8201;&#177;&#8201;53.36</td></tr>
###xml 2522 2536 2466 2480 <td xmlns:xlink="http://www.w3.org/1999/xlink">Raclopride 0.1</td>
###xml 2536 2550 2480 2494 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.075</td>
###xml 2550 2552 2494 2496 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2552 2569 2496 2511 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">218.04&#8201;&#177;&#8201;43.22*</td>
###xml 2522 2569 2466 2511 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Raclopride 0.1</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">218.04&#8201;&#177;&#8201;43.22*</td></tr>
###xml 2569 2576 2511 2518 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2576 2583 2518 2525 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2583 2585 2525 2527 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2585 2601 2527 2541 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">397.60&#8201;&#177;&#8201;86.39</td>
###xml 2569 2601 2511 2541 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">397.60&#8201;&#177;&#8201;86.39</td></tr>
###xml 2601 2615 2541 2555 <td xmlns:xlink="http://www.w3.org/1999/xlink">WAY 100635 1.0</td>
###xml 2615 2622 2555 2562 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2622 2624 2562 2564 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 2624 2640 2564 2578 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">300.35&#8201;&#177;&#8201;56.09</td>
###xml 2601 2640 2541 2578 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>WAY 100635 1.0</td><td>Vehicle</td><td char="." align="char">13</td><td char="&#177;" align="char">300.35&#8201;&#177;&#8201;56.09</td></tr>
###xml 2640 2647 2578 2585 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2647 2661 2585 2599 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.075</td>
###xml 2661 2663 2599 2601 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2663 2679 2601 2615 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">327.42&#8201;&#177;&#8201;46.89</td>
###xml 2640 2679 2578 2615 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">327.42&#8201;&#177;&#8201;46.89</td></tr>
###xml 2679 2693 2615 2629 <td xmlns:xlink="http://www.w3.org/1999/xlink">WAY 100635 1.0</td>
###xml 2693 2707 2629 2643 <td xmlns:xlink="http://www.w3.org/1999/xlink">Lisuride 0.075</td>
###xml 2707 2709 2643 2645 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 2709 2727 2645 2661 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">103.69&#8201;&#177;&#8201;12.20**</td>
###xml 2679 2727 2615 2661 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>WAY 100635 1.0</td><td>Lisuride 0.075</td><td char="." align="char">13</td><td char="&#177;" align="char">103.69&#8201;&#177;&#8201;12.20**</td></tr>
###xml 2727 2727 2661 2661 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="4"/>
###xml 2727 2734 2661 2668 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2734 2736 2668 2670 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2736 2753 2670 2685 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">543.67&#8201;&#177;&#8201;110.96</td>
###xml 2727 2753 2661 2685 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="4"/><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">543.67&#8201;&#177;&#8201;110.96</td></tr>
###xml 2753 2761 2685 2693 <td xmlns:xlink="http://www.w3.org/1999/xlink">LSD 0.05</td>
###xml 2761 2763 2693 2695 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2763 2779 2695 2709 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">320.74&#8201;&#177;&#8201;64.62</td>
###xml 2753 2779 2685 2709 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LSD 0.05</td><td char="." align="char">12</td><td char="&#177;" align="char">320.74&#8201;&#177;&#8201;64.62</td></tr>
###xml 2779 2786 2709 2716 <td xmlns:xlink="http://www.w3.org/1999/xlink">LSD 0.1</td>
###xml 2786 2788 2716 2718 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2788 2804 2718 2732 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">287.22&#8201;&#177;&#8201;65.86</td>
###xml 2779 2804 2709 2732 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">287.22&#8201;&#177;&#8201;65.86</td></tr>
###xml 2804 2811 2732 2739 <td xmlns:xlink="http://www.w3.org/1999/xlink">LSD 0.2</td>
###xml 2811 2813 2739 2741 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 2813 2829 2741 2755 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">252.93&#8201;&#177;&#8201;40.19</td>
###xml 2804 2829 2732 2755 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LSD 0.2</td><td char="." align="char">11</td><td char="&#177;" align="char">252.93&#8201;&#177;&#8201;40.19</td></tr>
###xml 2829 2836 2755 2762 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2836 2843 2762 2769 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2843 2845 2769 2771 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 2845 2861 2771 2785 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">261.74&#8201;&#177;&#8201;34.75</td>
###xml 2829 2861 2755 2785 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">261.74&#8201;&#177;&#8201;34.75</td></tr>
###xml 2861 2875 2785 2799 <td xmlns:xlink="http://www.w3.org/1999/xlink">MDL 11,939 0.3</td>
###xml 2875 2882 2799 2806 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2882 2884 2806 2808 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2884 2900 2808 2822 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">224.07&#8201;&#177;&#8201;26.19</td>
###xml 2861 2900 2785 2822 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">224.07&#8201;&#177;&#8201;26.19</td></tr>
###xml 2900 2907 2822 2829 <td xmlns:xlink="http://www.w3.org/1999/xlink">Vehicle</td>
###xml 2907 2914 2829 2836 <td xmlns:xlink="http://www.w3.org/1999/xlink">LSD 0.1</td>
###xml 2914 2916 2836 2838 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 2916 2932 2838 2852 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">248.88&#8201;&#177;&#8201;22.57</td>
###xml 2900 2932 2822 2852 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Vehicle</td><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">248.88&#8201;&#177;&#8201;22.57</td></tr>
###xml 2932 2946 2852 2866 <td xmlns:xlink="http://www.w3.org/1999/xlink">MDL 11,939 0.3</td>
###xml 2946 2953 2866 2873 <td xmlns:xlink="http://www.w3.org/1999/xlink">LSD 0.1</td>
###xml 2953 2955 2873 2875 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 2955 2971 2875 2889 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">262.89&#8201;&#177;&#8201;40.53</td>
###xml 2932 2971 2852 2889 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>MDL 11,939 0.3</td><td>LSD 0.1</td><td char="." align="char">11</td><td char="&#177;" align="char">262.89&#8201;&#177;&#8201;40.53</td></tr>
###xml 2136 2971 2102 2889 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td rowspan="4"/><td>Vehicle</td><td char="." align="char">9</td><td char="&#177;" align="char">457.95&#8201;&#177;&#8201;67.80</td></tr><tr><td>Lisuride 0.0375</td><td char="." align="char">10</td><td char="&#177;" align="char">221.68&#8201;&#177;&#8201;45.98*</td></tr><tr><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">247.43&#8201;&#177;&#8201;36.41</td></tr><tr><td>Lisuride 0.15</td><td char="." align="char">9</td><td char="&#177;" align="char">389.55&#8201;&#177;&#8201;69.80</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">275.30&#8201;&#177;&#8201;36.60</td></tr><tr><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">300.94&#8201;&#177;&#8201;44.15</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">178.96&#8201;&#177;&#8201;30.63</td></tr><tr><td>MDL 11,939 0.3</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">202.83&#8201;&#177;&#8201;29.89</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">437.63&#8201;&#177;&#8201;83.94</td></tr><tr><td>Raclopride 0.1</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">260.07&#8201;&#177;&#8201;29.69</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">11</td><td char="&#177;" align="char">262.48&#8201;&#177;&#8201;53.36</td></tr><tr><td>Raclopride 0.1</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">218.04&#8201;&#177;&#8201;43.22*</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">397.60&#8201;&#177;&#8201;86.39</td></tr><tr><td>WAY 100635 1.0</td><td>Vehicle</td><td char="." align="char">13</td><td char="&#177;" align="char">300.35&#8201;&#177;&#8201;56.09</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">327.42&#8201;&#177;&#8201;46.89</td></tr><tr><td>WAY 100635 1.0</td><td>Lisuride 0.075</td><td char="." align="char">13</td><td char="&#177;" align="char">103.69&#8201;&#177;&#8201;12.20**</td></tr><tr><td rowspan="4"/><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">543.67&#8201;&#177;&#8201;110.96</td></tr><tr><td>LSD 0.05</td><td char="." align="char">12</td><td char="&#177;" align="char">320.74&#8201;&#177;&#8201;64.62</td></tr><tr><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">287.22&#8201;&#177;&#8201;65.86</td></tr><tr><td>LSD 0.2</td><td char="." align="char">11</td><td char="&#177;" align="char">252.93&#8201;&#177;&#8201;40.19</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">261.74&#8201;&#177;&#8201;34.75</td></tr><tr><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">224.07&#8201;&#177;&#8201;26.19</td></tr><tr><td>Vehicle</td><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">248.88&#8201;&#177;&#8201;22.57</td></tr><tr><td>MDL 11,939 0.3</td><td>LSD 0.1</td><td char="." align="char">11</td><td char="&#177;" align="char">262.89&#8201;&#177;&#8201;40.53</td></tr></tbody>
###xml 2066 2971 2034 2889 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Pretreatment (mg/kg)</th><th>Treatment (mg/kg)</th><th><italic>n</italic></th><th>Startle magnitude (mean &#177; SEM)</th></tr></thead><tbody><tr><td rowspan="4"/><td>Vehicle</td><td char="." align="char">9</td><td char="&#177;" align="char">457.95&#8201;&#177;&#8201;67.80</td></tr><tr><td>Lisuride 0.0375</td><td char="." align="char">10</td><td char="&#177;" align="char">221.68&#8201;&#177;&#8201;45.98*</td></tr><tr><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">247.43&#8201;&#177;&#8201;36.41</td></tr><tr><td>Lisuride 0.15</td><td char="." align="char">9</td><td char="&#177;" align="char">389.55&#8201;&#177;&#8201;69.80</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">275.30&#8201;&#177;&#8201;36.60</td></tr><tr><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">300.94&#8201;&#177;&#8201;44.15</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">178.96&#8201;&#177;&#8201;30.63</td></tr><tr><td>MDL 11,939 0.3</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">202.83&#8201;&#177;&#8201;29.89</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">437.63&#8201;&#177;&#8201;83.94</td></tr><tr><td>Raclopride 0.1</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">260.07&#8201;&#177;&#8201;29.69</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">11</td><td char="&#177;" align="char">262.48&#8201;&#177;&#8201;53.36</td></tr><tr><td>Raclopride 0.1</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">218.04&#8201;&#177;&#8201;43.22*</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">397.60&#8201;&#177;&#8201;86.39</td></tr><tr><td>WAY 100635 1.0</td><td>Vehicle</td><td char="." align="char">13</td><td char="&#177;" align="char">300.35&#8201;&#177;&#8201;56.09</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">327.42&#8201;&#177;&#8201;46.89</td></tr><tr><td>WAY 100635 1.0</td><td>Lisuride 0.075</td><td char="." align="char">13</td><td char="&#177;" align="char">103.69&#8201;&#177;&#8201;12.20**</td></tr><tr><td rowspan="4"/><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">543.67&#8201;&#177;&#8201;110.96</td></tr><tr><td>LSD 0.05</td><td char="." align="char">12</td><td char="&#177;" align="char">320.74&#8201;&#177;&#8201;64.62</td></tr><tr><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">287.22&#8201;&#177;&#8201;65.86</td></tr><tr><td>LSD 0.2</td><td char="." align="char">11</td><td char="&#177;" align="char">252.93&#8201;&#177;&#8201;40.19</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">261.74&#8201;&#177;&#8201;34.75</td></tr><tr><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">224.07&#8201;&#177;&#8201;26.19</td></tr><tr><td>Vehicle</td><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">248.88&#8201;&#177;&#8201;22.57</td></tr><tr><td>MDL 11,939 0.3</td><td>LSD 0.1</td><td char="." align="char">11</td><td char="&#177;" align="char">262.89&#8201;&#177;&#8201;40.53</td></tr></tbody></table>
###xml 2972 2973 2890 2891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2984 2985 2902 2903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2971 3034 2889 2952 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">*<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 versus vehicle or vehicle&#8211;vehicle control</p>
###xml 2971 3034 2889 2952 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">*<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 versus vehicle or vehicle&#8211;vehicle control</p></table-wrap-foot>
###xml 2014 3034 1982 2952 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="33">Effect of drug treatment on startle magnitude</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Pretreatment (mg/kg)</th><th>Treatment (mg/kg)</th><th><italic>n</italic></th><th>Startle magnitude (mean &#177; SEM)</th></tr></thead><tbody><tr><td rowspan="4"/><td>Vehicle</td><td char="." align="char">9</td><td char="&#177;" align="char">457.95&#8201;&#177;&#8201;67.80</td></tr><tr><td>Lisuride 0.0375</td><td char="." align="char">10</td><td char="&#177;" align="char">221.68&#8201;&#177;&#8201;45.98*</td></tr><tr><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">247.43&#8201;&#177;&#8201;36.41</td></tr><tr><td>Lisuride 0.15</td><td char="." align="char">9</td><td char="&#177;" align="char">389.55&#8201;&#177;&#8201;69.80</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">275.30&#8201;&#177;&#8201;36.60</td></tr><tr><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">300.94&#8201;&#177;&#8201;44.15</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">10</td><td char="&#177;" align="char">178.96&#8201;&#177;&#8201;30.63</td></tr><tr><td>MDL 11,939 0.3</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">202.83&#8201;&#177;&#8201;29.89</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">437.63&#8201;&#177;&#8201;83.94</td></tr><tr><td>Raclopride 0.1</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">260.07&#8201;&#177;&#8201;29.69</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">11</td><td char="&#177;" align="char">262.48&#8201;&#177;&#8201;53.36</td></tr><tr><td>Raclopride 0.1</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">218.04&#8201;&#177;&#8201;43.22*</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">397.60&#8201;&#177;&#8201;86.39</td></tr><tr><td>WAY 100635 1.0</td><td>Vehicle</td><td char="." align="char">13</td><td char="&#177;" align="char">300.35&#8201;&#177;&#8201;56.09</td></tr><tr><td>Vehicle</td><td>Lisuride 0.075</td><td char="." align="char">12</td><td char="&#177;" align="char">327.42&#8201;&#177;&#8201;46.89</td></tr><tr><td>WAY 100635 1.0</td><td>Lisuride 0.075</td><td char="." align="char">13</td><td char="&#177;" align="char">103.69&#8201;&#177;&#8201;12.20**</td></tr><tr><td rowspan="4"/><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">543.67&#8201;&#177;&#8201;110.96</td></tr><tr><td>LSD 0.05</td><td char="." align="char">12</td><td char="&#177;" align="char">320.74&#8201;&#177;&#8201;64.62</td></tr><tr><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">287.22&#8201;&#177;&#8201;65.86</td></tr><tr><td>LSD 0.2</td><td char="." align="char">11</td><td char="&#177;" align="char">252.93&#8201;&#177;&#8201;40.19</td></tr><tr><td>Vehicle</td><td>Vehicle</td><td char="." align="char">11</td><td char="&#177;" align="char">261.74&#8201;&#177;&#8201;34.75</td></tr><tr><td>MDL 11,939 0.3</td><td>Vehicle</td><td char="." align="char">12</td><td char="&#177;" align="char">224.07&#8201;&#177;&#8201;26.19</td></tr><tr><td>Vehicle</td><td>LSD 0.1</td><td char="." align="char">12</td><td char="&#177;" align="char">248.88&#8201;&#177;&#8201;22.57</td></tr><tr><td>MDL 11,939 0.3</td><td>LSD 0.1</td><td char="." align="char">11</td><td char="&#177;" align="char">262.89&#8201;&#177;&#8201;40.53</td></tr></tbody></table><table-wrap-foot><p textid="34">*<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 versus vehicle or vehicle&#8211;vehicle control</p></table-wrap-foot></table-wrap>
###xml 1370 1374 <span type="species:ncbi:10116">rats</span>
As shown in Fig. 1, administration of lisuride significantly reduced PPI [F(3,34) = 12.74, p < 0.0001]. Post hoc comparisons confirmed that all three doses of lisuride decreased PPI (p < 0.05, 0.01). There was a significant main effect of prepulse intensity [F(2,68) = 7.82, p = 0.0009; this effect was observed in all subsequent experiments], and there was a significant interaction between lisuride and prepulse intensity [F(6,68) = 3.11, p < 0.01]. Inspection of the data revealed significant effects of 37.5 microg/kg lisuride only for the 68- and 71-dB prepulse intensities (3 and 6 dB over background; p < 0.05, 0.01), whereas 75 microg/kg lisuride significantly decreased PPI only at the 71- and 77-dB prepulse intensities (p < 0.01). Administration of 75 microg/kg lisuride decreased PPI at the 68-dB prepulse intensity, and this effect approached but did not reach significance (p < 0.1). The highest dose of lisuride tested (150 microg/kg) decreased PPI at all three prepulse intensities (p < 0.01). There was an effect of lisuride on startle amplitude during block 2 [F(3,34) = 4.16, p < 0.02]. Post hoc comparisons revealed that 37.5 microg/kg lisuride significantly decreased startle magnitude (p < 0.05; Table 1). To confirm that the effect of lisuride on PPI is independent of changes in startle, we examined the effect of lisuride on PPI in subgroups of rats that were matched for block 2 startle magnitude (mean +/- SEM = 320.32 +/- 24.68, 261.72 +/- 17.98, 257.28 +/- 14.68, and 299.88 +/- 21.23). Although lisuride had no effect on startle magnitude in those animals [F(3,16) = 2.32, p < 0.2 NS], PPI was still significantly reduced [F(3,16) = 4.97, p < 0.02]. Fig. 1Left panel Effects of lisuride (0.0375, 0.075, and 0.15 mg/kg, s.c.) on prepulse inhibition. Right panel Effects of lisuride averaged across the three prepulse intensities. Values represent mean +/- SEM for each group. Drug doses are in milligram per kilogram. *p < 0.05, **p < 0.01, significantly different from vehicle controlTable 1Effect of drug treatment on startle magnitudePretreatment (mg/kg)Treatment (mg/kg)nStartle magnitude (mean +/- SEM)Vehicle9457.95 +/- 67.80Lisuride 0.037510221.68 +/- 45.98*Lisuride 0.07510247.43 +/- 36.41Lisuride 0.159389.55 +/- 69.80VehicleVehicle11275.30 +/- 36.60MDL 11,939 0.3Vehicle12300.94 +/- 44.15VehicleLisuride 0.07510178.96 +/- 30.63MDL 11,939 0.3Lisuride 0.07512202.83 +/- 29.89VehicleVehicle12437.63 +/- 83.94Raclopride 0.1Vehicle11260.07 +/- 29.69VehicleLisuride 0.07511262.48 +/- 53.36Raclopride 0.1Lisuride 0.07512218.04 +/- 43.22*VehicleVehicle12397.60 +/- 86.39WAY 100635 1.0Vehicle13300.35 +/- 56.09VehicleLisuride 0.07512327.42 +/- 46.89WAY 100635 1.0Lisuride 0.07513103.69 +/- 12.20**Vehicle12543.67 +/- 110.96LSD 0.0512320.74 +/- 64.62LSD 0.112287.22 +/- 65.86LSD 0.211252.93 +/- 40.19VehicleVehicle11261.74 +/- 34.75MDL 11,939 0.3Vehicle12224.07 +/- 26.19VehicleLSD 0.112248.88 +/- 22.57MDL 11,939 0.3LSD 0.111262.89 +/- 40.53*p < 0.05, **p < 0.01 versus vehicle or vehicle-vehicle control
###end p 31
###begin p 32
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 93 104 93 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 262 263 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 274 275 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Left panel Effects of lisuride (0.0375, 0.075, and 0.15 mg/kg, s.c.) on prepulse inhibition. Right panel Effects of lisuride averaged across the three prepulse intensities. Values represent mean +/- SEM for each group. Drug doses are in milligram per kilogram. *p < 0.05, **p < 0.01, significantly different from vehicle control
###end p 32
###begin p 33
Effect of drug treatment on startle magnitude
###end p 33
###begin p 34
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
*p < 0.05, **p < 0.01 versus vehicle or vehicle-vehicle control
###end p 34
###begin title 35
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
Experiment 2: lisuride versus the 5-HT2A antagonist MDL 11,939
###end title 35
###begin p 36
###xml 75 76 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 92 93 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 290 292 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2a</xref>
###xml 364 366 360 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 435 439 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 576 577 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 580 586 576 582 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 597 598 593 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 617 619 613 615 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 643 644 639 640 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 650 651 646 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 653 654 649 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 682 683 678 679 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 810 811 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 822 823 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 882 883 876 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 883 884 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 586 946 582 940 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Effects of <bold>a</bold> the selective 5-HT<sub>2A</sub> antagonist MDL 11,939, <bold>b</bold> the D<sub>2</sub>/D<sub>3</sub> antagonist raclopride, and <bold>c</bold> the 5-HT1A antagonist WAY-100635 on the disruption of PPI induced by lisuride. Values represent mean &#177; SEM for each group. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control, and <sup>#</sup><italic>p</italic>&#8201;&lt;&#8201;0.05, significantly different from lisuride-treated animals</p>
###xml 586 946 582 940 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Effects of <bold>a</bold> the selective 5-HT<sub>2A</sub> antagonist MDL 11,939, <bold>b</bold> the D<sub>2</sub>/D<sub>3</sub> antagonist raclopride, and <bold>c</bold> the 5-HT1A antagonist WAY-100635 on the disruption of PPI induced by lisuride. Values represent mean &#177; SEM for each group. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control, and <sup>#</sup><italic>p</italic>&#8201;&lt;&#8201;0.05, significantly different from lisuride-treated animals</p></caption>
###xml 946 946 940 940 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="213_2009_1718_Fig2_HTML" id="MO2"/>
###xml 580 946 576 940 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="37">Effects of <bold>a</bold> the selective 5-HT<sub>2A</sub> antagonist MDL 11,939, <bold>b</bold> the D<sub>2</sub>/D<sub>3</sub> antagonist raclopride, and <bold>c</bold> the 5-HT1A antagonist WAY-100635 on the disruption of PPI induced by lisuride. Values represent mean &#177; SEM for each group. *<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control, and <sup>#</sup><italic>p</italic>&#8201;&lt;&#8201;0.05, significantly different from lisuride-treated animals</p></caption><graphic position="anchor" xlink:href="213_2009_1718_Fig2_HTML" id="MO2"/></fig>
As expected, 75 microg/kg lisuride produced a significant decrease in PPI [F(1,41) = 34.62, p < 0.0001]. However, there was no significant interaction between pretreatment and treatment, indicating that the effect of lisuride was not blocked by pretreatment with 0.3 mg/kg MDL 11,939 (Fig. 2a). The dose of MDL 11,939 used was previously demonstrated to block 5-HT2A receptor-mediated behavioral effects completely (Halberstadt et al. 2008). Pretreatment with MDL 11,939 had no effect on PPI. Neither pretreatment nor treatment significantly affected startle magnitude (Table 1). Fig. 2Effects of a the selective 5-HT2A antagonist MDL 11,939, b the D2/D3 antagonist raclopride, and c the 5-HT1A antagonist WAY-100635 on the disruption of PPI induced by lisuride. Values represent mean +/- SEM for each group. *p < 0.05, **p < 0.01, significantly different from vehicle control, and #p < 0.05, significantly different from lisuride-treated animals
###end p 36
###begin p 37
###xml 11 12 11 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 57 58 57 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 64 65 64 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 96 97 96 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 224 225 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 236 237 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 296 297 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 297 298 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Effects of a the selective 5-HT2A antagonist MDL 11,939, b the D2/D3 antagonist raclopride, and c the 5-HT1A antagonist WAY-100635 on the disruption of PPI induced by lisuride. Values represent mean +/- SEM for each group. *p < 0.05, **p < 0.01, significantly different from vehicle control, and #p < 0.05, significantly different from lisuride-treated animals
###end p 37
###begin title 38
###xml 35 38 35 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3</sub>
Experiment 3: lisuride versus the D2/3 antagonist raclopride
###end title 38
###begin p 39
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 164 165 164 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 180 181 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2b</xref>
###xml 296 297 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 370 371 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 386 387 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 512 513 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 528 529 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 553 554 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 569 570 565 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 622 623 618 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1056 1057 1052 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1090 1091 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1166 1167 1162 1163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1260 1261 1256 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1276 1277 1272 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1353 1354 1349 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1369 1370 1365 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 917 921 <span type="species:ncbi:10116">rats</span>
Administration of lisuride produced a significant decrease in PPI [F(1,42) = 14.39, p = 0.0005]. There was a significant interaction of pretreatment and treatment [F(1,42) = 6.18, p < 0.02]. As shown in Fig. 2b, 0.1 mg/kg raclopride blocked the reduction of PPI induced by 75 microg/kg lisuride (p < 0.05). There was a trend toward a main effect of pretreatment on PPI [F(1,42) = 2.90, p < 0.1], but this effect was not confirmed by post hoc analysis. There were also trends toward main effects of pretreatment [F(1,42) = 3.74, p < 0.06] and treatment [F(1,42) = 3.58, p < 0.07] on startle amplitude during block 2 (Table 1). However, there was no interaction between treatment and pretreatment for startle amplitude. To confirm that the ability of raclopride to block the lisuride-induced decrease in PPI is independent of changes in startle, we examined the effect of raclopride and lisuride on PPI in subgroups of rats that were matched for block 2 startle magnitude. Startle magnitude in that subset of animals was not affected by either pretreatment [F(1,20) = 0.00, NS] or treatment [F(1,20) = 0.63, NS], and there was no pretreatment x treatment interaction [F(1,20) = 1.39, NS]. Nonetheless, for PPI, there was still a significant effect of treatment [F(1,20) = 5.76, p < 0.03], and a significant interaction between pretreatment and treatment [F(1,20) = 6.68, p < 0.02].
###end p 39
###begin title 40
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
Experiment 4: lisuride versus the 5-HT1A antagonist WAY-100635
###end title 40
###begin p 41
###xml 84 85 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 101 102 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 294 296 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2c</xref>
###xml 340 341 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 356 357 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 382 383 378 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 398 399 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 623 624 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
There was a significant decrease in PPI after treatment with 75 microg/kg lisuride [F(1,46) = 22.75, p < 0.0001], but there was no significant interaction between pretreatment and treatment, indicating that the effect of lisuride was not blocked by pretreatment with 1.0 mg/kg WAY-100635 (Fig. 2c). There were main effects of pretreatment [F(1,46) = 8.37, p < 0.006] and treatment [F(1,46) = 5.78, p < 0.03] on startle amplitude, but no interaction between pretreatment and treatment. Post hoc comparisons demonstrated that startle amplitude was only significantly reduced in the WAY-100635-lisuride treatment group (Table 1).
###end p 41
###begin title 42
Experiment 5: LSD dose response
###end title 42
###begin p 43
###xml 47 51 47 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2001</xref>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 121 122 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 284 285 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 352 353 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 368 369 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 488 489 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 566 567 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 644 645 636 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 655 661 647 653 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 661 671 653 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 744 755 736 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 908 909 898 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 921 922 911 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 661 975 653 965 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44"><italic>Left panel</italic> Effects of LSD (0.05, 0.1, and 0.2&#160;mg/kg, s.c.) on prepulse inhibition. <italic>Right panel</italic> Effects of LSD averaged across the three prepulse intensities. Values represent mean &#177; SEM for each group. Drug doses are in milligram per kilogram. *<italic>p</italic>&#8201;&lt;&#8201;0.05, ** <italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control</p>
###xml 661 975 653 965 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44"><italic>Left panel</italic> Effects of LSD (0.05, 0.1, and 0.2&#160;mg/kg, s.c.) on prepulse inhibition. <italic>Right panel</italic> Effects of LSD averaged across the three prepulse intensities. Values represent mean &#177; SEM for each group. Drug doses are in milligram per kilogram. *<italic>p</italic>&#8201;&lt;&#8201;0.05, ** <italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control</p></caption>
###xml 975 975 965 965 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="213_2009_1718_Fig3_HTML" id="MO3"/>
###xml 655 975 647 965 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="44"><italic>Left panel</italic> Effects of LSD (0.05, 0.1, and 0.2&#160;mg/kg, s.c.) on prepulse inhibition. <italic>Right panel</italic> Effects of LSD averaged across the three prepulse intensities. Values represent mean &#177; SEM for each group. Drug doses are in milligram per kilogram. *<italic>p</italic>&#8201;&lt;&#8201;0.05, ** <italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control</p></caption><graphic position="anchor" xlink:href="213_2009_1718_Fig3_HTML" id="MO3"/></fig>
###xml 525 529 <span type="species:ncbi:10116">rats</span>
Confirming a previous report (Ouagazzal et al. 2001), there was a significant main effect of LSD on PPI [F(3,43) = 6.60, p = 0.0009]. There was no treatment x intensity interaction. Figure 3 shows that the two highest doses of LSD (100 and 200 microg/kg) significantly decreased PPI (p < 0.01). There was an overall effect of LSD on startle amplitude [F(3,43) = 2.99, p < 0.05]. Tukey's test revealed that 100 and 200 microg/kg LSD induced a nonsignificant decrease in startle magnitude (p < 0.1). However, when subgroups of rats were matched for startle magnitude [F(3,20) = 0.57, NS], LSD was still capable of decreasing PPI [F(3,20) = 3.60, p < 0.04]. Fig. 3Left panel Effects of LSD (0.05, 0.1, and 0.2 mg/kg, s.c.) on prepulse inhibition. Right panel Effects of LSD averaged across the three prepulse intensities. Values represent mean +/- SEM for each group. Drug doses are in milligram per kilogram. *p < 0.05, ** p < 0.01, significantly different from vehicle control
###end p 43
###begin p 44
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 83 94 83 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 247 248 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 260 261 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Left panel Effects of LSD (0.05, 0.1, and 0.2 mg/kg, s.c.) on prepulse inhibition. Right panel Effects of LSD averaged across the three prepulse intensities. Values represent mean +/- SEM for each group. Drug doses are in milligram per kilogram. *p < 0.05, ** p < 0.01, significantly different from vehicle control
###end p 44
###begin title 45
###xml 33 35 33 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
Experiment 6: LSD versus the 5-HT2A antagonist MDL 11,939
###end title 45
###begin p 46
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 214 215 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 276 277 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 293 294 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 385 386 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 442 443 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 459 460 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 623 624 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 627 633 619 625 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 661 663 653 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 775 776 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 835 837 825 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 837 838 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 633 895 625 885 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Effect of the selective 5-HT<sub>2A</sub> antagonist MDL 11,939 on the disruption of PPI induced by LSD. Values represent mean &#177; SEM for each group. **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control, and <sup>##</sup><italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from LSD-treated animals</p>
###xml 633 895 625 885 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Effect of the selective 5-HT<sub>2A</sub> antagonist MDL 11,939 on the disruption of PPI induced by LSD. Values represent mean &#177; SEM for each group. **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control, and <sup>##</sup><italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from LSD-treated animals</p></caption>
###xml 895 895 885 885 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="213_2009_1718_Fig4_HTML" id="MO4"/>
###xml 627 895 619 885 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="47">Effect of the selective 5-HT<sub>2A</sub> antagonist MDL 11,939 on the disruption of PPI induced by LSD. Values represent mean &#177; SEM for each group. **<italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from vehicle control, and <sup>##</sup><italic>p</italic>&#8201;&lt;&#8201;0.01, significantly different from LSD-treated animals</p></caption><graphic position="anchor" xlink:href="213_2009_1718_Fig4_HTML" id="MO4"/></fig>
There was an interaction between pretreatment and treatment [F(1,42) = 4.23, p < 0.05]. Figure 4 shows that the disruption of PPI produced by 100 microg/kg LSD was significantly attenuated by 0.3 mg/kg MDL 11,939 (p < 0.01). As expected, there was a main effect of treatment [F(1,42) = 12.86, p = 0.0009]. Post hoc analysis revealed that 100 microg/kg LSD significantly decreased PPI (p < 0.01). There was also a main effect of pretreatment [F(1,42) = 10.05, p < 0.003], but this effect was not confirmed by post hoc analysis. There was no significant effect of either pretreatment or treatment on startle magnitude (Table 1). Fig. 4Effect of the selective 5-HT2A antagonist MDL 11,939 on the disruption of PPI induced by LSD. Values represent mean +/- SEM for each group. **p < 0.01, significantly different from vehicle control, and ##p < 0.01, significantly different from LSD-treated animals
###end p 46
###begin p 47
###xml 28 30 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 142 143 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 202 204 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 204 205 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Effect of the selective 5-HT2A antagonist MDL 11,939 on the disruption of PPI induced by LSD. Values represent mean +/- SEM for each group. **p < 0.01, significantly different from vehicle control, and ##p < 0.01, significantly different from LSD-treated animals
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 127 128 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 238 240 238 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 386 388 386 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2002</xref>
###xml 449 451 449 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 528 533 528 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR63">1995b</xref>
###xml 606 608 606 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 715 716 715 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 718 719 718 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 745 747 745 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 755 757 755 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 882 886 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2001</xref>
###xml 907 911 907 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2001</xref>
###xml 1015 1017 1015 1017 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1081 1082 1081 1082 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1084 1085 1084 1085 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 92 96 <span type="species:ncbi:10116">rats</span>
###xml 506 510 <span type="species:ncbi:10116">rats</span>
The present study demonstrated that lisuride produced a dose-dependent disruption of PPI in rats. The selective dopamine (DA) D2/D3 receptor antagonist raclopride blocked the lisuride-induced PPI disruption. Conversely, the selective 5-HT2A antagonist MDL 11,939 did not prevent the disruption of PPI by lisuride. Although lisuride is a potent and highly efficacious agonist at the 5-HT1A receptor (Marona-Lewicka et al. 2002) and activation of 5-HT1A receptors has previously been shown to disrupt PPI in rats (Sipes and Geyer 1995b), we were unable to block the effect of lisuride with the selective 5-HT1A antagonist WAY-100635. These results strongly indicate that the effect of lisuride on PPI is mediated by D2/D3 receptors and not by 5-HT2A or 5-HT1A receptors. We also tested the effect of LSD and found that LSD disrupts PPI, confirming a previous report (Ouagazzal et al. 2001). Ouagazzal et al. (2001) also reported that the ability of LSD to reduce PPI is blocked by pretreatment with the selective 5-HT2A antagonist M100907 but is unaffected by pretreatment with the D2/D3 antagonist haloperidol. Likewise, we found that MDL 11,939 blocked LSD-induced disruption of PPI. Thus, although LSD and lisuride both disrupt PPI, they do so by different receptor mechanisms.
###end p 49
###begin p 50
###xml 54 55 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 177 178 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 216 217 216 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 217 218 217 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">1996</xref>
###xml 326 327 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 333 334 333 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 369 374 369 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2002a</xref>
###xml 413 414 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 435 436 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">1991</xref>
###xml 680 684 680 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR75">1983</xref>
###xml 686 690 686 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR76">1984</xref>
###xml 971 975 971 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">1978</xref>
###xml 1211 1215 1211 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1985</xref>
###xml 1318 1319 1318 1319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1372 1376 1372 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1982</xref>
###xml 1392 1396 1392 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">1991</xref>
###xml 1415 1419 1415 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR78">1991</xref>
###xml 514 517 <span type="species:ncbi:10116">rat</span>
###xml 870 874 <span type="species:ncbi:10116">rats</span>
The finding that lisuride disrupts PPI by activating D2/D3 receptors is consistent with previous evidence demonstrating that lisuride is a dopaminergic drug. Lisuride binds to D2 and D3 receptors with high affinity (Ki values of 0.3 and 1.7 nM, respectively; Piercey et al. 1996) and acts as a partial agonist at recombinant D2 and D3 receptors (Newman-Tancredi et al. 2002a). Autoradiography has confirmed that [3H]lisuride binds to D2-like receptors in the striatum, nucleus accumbens, and olfactory tubercle in rat brain (Kimura et al. 1991). Lisuride has also been shown to directly inhibit the firing of A10 dopaminergic neurons in the ventral tegmental area (White and Wang 1983, 1984), indicating that it activates DA autoreceptors. Behavioral studies also demonstrate that lisuride has DA agonist activity. For example, lisuride induces contralateral turning in rats with unilateral 6-hydroxydopamine-induced lesions of the nigrostriatal DA pathway (Pieri et al. 1978), an effect that is consistent with direct activation of postsynaptic DA receptors. The effects of lisuride on locomotor activity are also similar to those of the DA agonist apomorphine and different from those of LSD (Adams and Geyer 1985). Furthermore, in drug discrimination studies, lisuride produces symmetrical generalization with the D2 agonists apomorphine and terguride (Holohean et al. 1982; Kimura et al. 1991; Yamaguchi et al. 1991).
###end p 50
###begin p 51
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 107 111 107 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2002</xref>
###xml 167 168 167 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR73">1995</xref>
###xml 391 395 391 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2001</xref>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">1978</xref>
###xml 786 788 786 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 966 968 966 968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 1002 1006 1002 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2009</xref>
###xml 663 667 <span type="species:ncbi:10116">rats</span>
LSD, like lisuride, is a dopaminergic agent. LSD binds to D1, D2, D3, D4, and D5 receptors (Nichols et al. 2002) and has been reported to act as a partial agonist at D1 receptors (Watts et al. 1995). Although we did not test whether raclopride blocks the effect of LSD on PPI, it was previously reported that haloperidol fails to attenuate the PPI-disruptive effect of LSD (Ouagazzal et al. 2001). Drug discrimination studies have also shown that dopaminergic activity does not contribute to the behavioral effects of LSD (Kuhn et al. 1978). However, recent evidence indicates that the dopaminergic effects of LSD may be time-dependent. Studies that have trained rats to discriminate LSD have typically used pretreatment times ranging from 15 to 30 min and have reliably shown that 5-HT2A antagonists block LSD-induced stimulus control. When a longer pretreatment time of 90 min is used, however, the resulting LSD cue is mediated by DA receptors rather than by 5-HT2A receptors (Marona-Lewicka et al. 2009). This finding raises the possibility that LSD may disrupt PPI via a dopaminergic mechanism if long pretreatment times are used.
###end p 51
###begin p 52
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR57">1979</xref>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">1981</xref>
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">1981</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR67">1991</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR69">1980</xref>
###xml 609 613 609 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">1994</xref>
###xml 630 634 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR58">2002</xref>
###xml 827 831 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR68">1984</xref>
###xml 1070 1074 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR67">1991</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
###xml 721 729 <span type="species:ncbi:9606">patients</span>
###xml 927 935 <span type="species:ncbi:9606">patients</span>
As was noted earlier, lisuride has been tested in numerous clinical trials, but it has never been shown that the drug can produce hallucinogenic effects in normal individuals. Parkinsonism patients treated chronically with high daily doses of lisuride have been reported to experience CNS side effects, including confusion and hallucinations (Schachter et al. 1979; Lieberman et al. 1981; Gopinathan et al. 1981; Vaamonde et al. 1991). However, chronic administration of equivalent doses of lisuride to non-parkinsonian patients does not produce any significant CNS sequelae (Verde et al. 1980; Gillin et al. 1994; Schmidt et al. 2002). The DA agonist bromocriptine is also known to elicit hallucinations in Parkinsonism patients, an effect that is not observed when the drug is used to treat endocrine disorders (Vance et al. 1984). It is therefore likely that the ability of lisuride to induce hallucinations in Parkinsonism patients is due to its potent dopaminergic activity combined with underlying neuropathology, rather than to a LSD-like effect (Vaamonde et al. 1991).
###end p 52
###begin p 53
###xml 180 182 180 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 245 247 245 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 350 352 350 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 720 722 720 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 871 873 871 873 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 494 500 <span type="species:ncbi:9606">humans</span>
###xml 687 693 <span type="species:ncbi:9606">humans</span>
Although both LSD and lisuride produce PPI disruption, we found that the receptors involved in the effects of these two drugs are distinct. Despite the fact that lisuride is a 5-HT2A agonist, it did not disrupt PPI via a mechanism involving 5-HT2A receptors, indicating that PPI can be used to differentiate hallucinogenic and non-hallucinogenic 5-HT2A agonists. This is an important finding because PPI is a cross-species behavioral paradigm that is altered by hallucinogens in animals and in humans. Tests with HTR have also demonstrated that there are behavioral differences between LSD and lisuride, but unfortunately HTR is not analogous to any behavior induced by hallucinogens in humans. The finding that the 5-HT2A receptor is not involved in the effect of lisuride on PPI provides additional support for the classification of lisuride as a nonhallucinogenic 5-HT2A agonist.
###end p 53
###begin p 54
###xml 172 174 172 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 246 248 246 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2002</xref>
###xml 373 377 373 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 440 442 440 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 483 485 483 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">1991</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1999</xref>
###xml 645 647 645 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 672 676 672 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">1991</xref>
###xml 691 695 691 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR56">1994</xref>
###xml 783 785 783 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 808 812 808 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1998</xref>
###xml 814 818 814 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2000</xref>
###xml 843 848 843 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">2002b</xref>
###xml 872 876 872 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2002</xref>
###xml 892 896 892 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2008</xref>
###xml 988 990 988 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
Several explanations have been proposed to account for the fact lisuride is not hallucinogenic. There has been speculation that the potent interaction of lisuride with 5-HT1A receptors may be acting to functionally antagonize the response to 5-HT2A receptor activation (Marona-Lewicka et al. 2002), but recent findings do not support this hypothesis (Gonzalez-Maeso et al. 2007). Data have also been published, indicating that LSD is a 5-HT2C agonist, whereas lisuride acts as a 5-HT2C antagonist (Burris et al. 1991; Fitzgerald et al. 1999), and it has been proposed that lisuride may be non-hallucinogenic because it fails to activate the 5-HT2C receptor (Burris et al. 1991; Sanders-Bush 1994). However, other studies have demonstrated that lisuride acts as an agonist at the 5-HT2C receptor (Egan et al. 1998, 2000; Newman-Tancredi et al. 2002b; Marona-Lewicka et al. 2002; Cussac et al. 2008). It is therefore unlikely that differences between the effects of LSD and lisuride on 5-HT2C receptors account for the inactivity of the latter drug.
###end p 54
###begin p 55
###xml 23 27 23 27 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">1995</xref>
###xml 443 447 443 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11</sub>
###xml 470 472 470 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 553 558 553 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">egr-1</italic>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">egr-2</italic>
###xml 610 613 610 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i/o</sub>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 727 731 <span type="species:ncbi:10090">mice</span>
Gonzalez-Maeso et al. (2007) suggested that differences in the behavioral effects of LSD and lisuride may be due to agonist-directed trafficking of 5-HT2A responses. Agonist-directed trafficking, or functional selectivity, refers to the phenomenon where receptors can couple independently to multiple effector mechanisms, and agonists may selectively activate a subset of the signaling pathways (Kenakin 1995). Both LSD and lisuride activate Gq/11 signaling via the 5-HT2A receptor. Conversely, LSD but not lisuride increases the cortical expression of egr-1 and egr-2 by activating pertussis toxin-sensitive Gi/o proteins and Src (Gonzalez-Maeso et al. 2007). These workers also found that lisuride does not induce the HTR in mice and proposed that LSD and other hallucinogens are capable of inducing this behavioral response because they activate specific signaling mechanisms that are not recruited by lisuride.
###end p 55
###begin p 56
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">1985</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 268 283 268 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cryptotis parva</italic>
###xml 300 304 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">1994</xref>
###xml 457 459 457 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 543 544 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q</sub>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2007</xref>
###xml 606 610 606 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11</sub>
###xml 619 621 619 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">is</italic>
###xml 659 661 659 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 752 756 752 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11</sub>
###xml 157 161 <span type="species:ncbi:10116">rats</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 255 266 <span type="species:ncbi:183661">least shrew</span>
###xml 268 283 <span type="species:ncbi:183661">Cryptotis parva</span>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
Two key findings in the literature, however, do not support the agonist-directed trafficking hypothesis. First, although lisuride does not induce the HTR in rats (Gerber et al. 1985) or mice (Gonzalez-Maeso et al. 2007), it does evoke the behavior in the least shrew (Cryptotis parva; Darmani et al. 1994). Thus, lisuride can induce head twitch under certain conditions (administration to a species that is highly sensitive to the behavioral effects of 5-HT2A agonists). Second, the ability of DOI to induce the HTR is markedly attenuated in Gq -/- knockout mice (Garcia et al. 2007), indicating that the Gq/11 pathway is involved in mediating the HTR to 5-HT2A activation. The latter finding is significant because both LSD and lisuride activate the Gq/11 pathway.
###end p 56
###begin p 57
###xml 25 29 25 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2008</xref>
###xml 80 84 80 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11</sub>
###xml 165 167 165 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 329 330 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q</sub>
###xml 389 391 389 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 427 431 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2007</xref>
###xml 513 515 513 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 605 608 605 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i/o</sub>
###xml 727 729 727 729 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 155 160 <span type="species:ncbi:9606">human</span>
Recently, Cussac et al. (2008) compared the efficacies of LSD and lisuride for Gq/11 activation and calcium mobilization in CHO cells transfected with the human 5-HT2A receptor. LSD activated both pathways with high efficacy, whereas lisuride was less efficacious, having only 57% of the efficacy of LSD. Based on the fact that Gq plays a role in transducing the behavioral effects of 5-HT2A receptor activation (Garcia et al. 2007), these workers proposed that lisuride may have insufficient efficacy at the 5-HT2A receptor to induce HTR and other behavioral effects. Thus, lisuride may fail to recruit Gi/o not because of agonist-directed receptor trafficking but rather because it has very low intrinsic efficacy at the 5-HT2A receptor.
###end p 57
###begin p 58
###xml 195 197 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">1985</xref>
###xml 321 326 321 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1995b</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">1991</xref>
###xml 784 785 784 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 827 829 827 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 905 909 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2002</xref>
Results obtained using the drug discrimination paradigm are consistent with the hypothesis that lisuride fails to induce hallucinogenic effects because it has relatively weak efficacy at the 5-HT2A receptor in vivo. Even though the DOM stimulus completely generalizes to lisuride (Glennon and Hauck 1985; Fiorella et al. 1995b), DOM-induced stimulus control is attenuated when the training drug is co-administered with lisuride (Glennon 1991). Thus, the effects of lisuride in the drug discrimination paradigm are consistent with the behavior of a partial agonist. As would be expected for a partial agonist, lisuride is active when administered alone but acts as an antagonist when administered in combination with a more efficacious agonist (e.g., DOM). Indeed, using formation of [3H]inositol phosphates as a measure of 5-HT2A agonist efficacy, lisuride is only 20% as efficacious as DOM (Rabin et al. 2002).
###end p 58
###begin p 59
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">1999</xref>
###xml 336 340 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">1980</xref>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2003</xref>
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 998 1000 998 1000 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 863 869 <span type="species:ncbi:9606">humans</span>
Regardless of the underlying mechanism, there is substantial evidence that LSD and lisuride evoke distinct neurochemical and behavioral effects. It has been demonstrated that lisuride fails to mimic fully the effects of LSD on the activity of neurons in prefrontal cortex (Arvanov et al. 1999) and facial nucleus (McCall and Aghajanian 1980). Furthermore, there are marked differences in the effects of lisuride and LSD on gene expression (Gonzalez-Maeso et al. 2003, 2007). Studies with head twitch indicate that this behavior is sensitive to LSD but not lisuride, at least in certain species. The present investigation extends those previous findings by demonstrating that different receptor mechanisms are responsible for the effects of LSD and lisuride on PPI. Further work is needed to clarify how these findings relate to the effects of LSD and lisuride in humans. Nevertheless, this study demonstrates that PPI can serve as a useful tool to compare hallucinogenic and non-hallucinogenic 5-HT2A agonists.
###end p 59
###begin p 60
This work was supported by National Institute on Drug Abuse Awards DA002925 and DA025412 and the Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center. M.A. Geyer holds an equity interest in San Diego Instruments, Inc.
###end p 60
###begin p 61
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 61
###begin title 62
References
###end title 62
###begin article-title 63
###xml 27 31 <span type="species:ncbi:10116">rats</span>
Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide
###end article-title 63
###begin article-title 64
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 101 104 <span type="species:ncbi:10116">rat</span>
LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex
###end article-title 64
###begin article-title 65
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease
###end article-title 65
###begin article-title 66
###xml 98 100 98 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1C</sub>
(+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5-HT1C receptor agonist
###end article-title 66
###begin article-title 67
###xml 59 61 59 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 67 69 67 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2B</sub>
###xml 78 84 78 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C-VSV</sub>
Agonist-directed trafficking of signaling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells
###end article-title 67
###begin article-title 68
###xml 45 60 45 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cryptotis parva</italic>
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 88 90 88 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1C</sub>
###xml 32 43 <span type="species:ncbi:183661">least shrew</span>
###xml 45 60 <span type="species:ncbi:183661">Cryptotis parva</span>
The head twitch response in the least shrew (Cryptotis parva) is a 5-HT2- and not a 5-HT1C-mediated phenomenon
###end article-title 68
###begin article-title 69
###xml 50 52 50 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 60 62 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors
###end article-title 69
###begin article-title 70
###xml 123 125 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 134 136 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
Agonist high and low state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT2A and 5-HT2C receptors
###end article-title 70
###begin article-title 71
###xml 20 22 20 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis
###end article-title 71
###begin article-title 72
Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: reassessment of LSD false positives
###end article-title 72
###begin article-title 73
###xml 103 105 103 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 114 116 114 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 83 88 <span type="species:ncbi:9606">human</span>
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action
###end article-title 73
###begin article-title 74
Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane
###end article-title 74
###begin article-title 75
###xml 62 66 <span type="species:ncbi:10116">rats</span>
Antagonism of L-5-hydroxytryptophan-induced head-twitching in rats by lisuride: a mixed 5-hydroxytryptamine agonist-antagonist?
###end article-title 75
###begin article-title 76
Serotonin research: contributions to understanding psychoses
###end article-title 76
###begin article-title 77
The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report
###end article-title 77
###begin article-title 78
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Do classical hallucinogens act as 5-HT2 agonists or antagonists?
###end article-title 78
###begin article-title 79
Discriminative stimulus properties of hallucinogens and related designer drugs
###end article-title 79
###begin article-title 80
Mechanistic studies on DOM as a discriminative stimulus
###end article-title 80
###begin article-title 81
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Evidence for 5-HT2 involvement in the mechanisms of action of hallucinogenic agents
###end article-title 81
###begin article-title 82
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
Transcriptome fingerprints distinguish hallucinogenic and non-hallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex
###end article-title 82
###begin article-title 83
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
###end article-title 83
###begin article-title 84
Lisuride in parkinsonism
###end article-title 84
###begin article-title 85
Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum
###end article-title 85
###begin article-title 86
###xml 92 96 <span type="species:ncbi:10116">rats</span>
Modification of the effects of 5-methoxy-N, N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
###end article-title 86
###begin article-title 87
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 15 17 15 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice
###end article-title 87
###begin article-title 88
Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide
###end article-title 88
###begin article-title 89
Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids
###end article-title 89
###begin article-title 90
###xml 33 37 <span type="species:ncbi:9685">cats</span>
Behavioral effects of LSD in the cats: proposal of an animal behavioral model for studying the actions of hallucinogenic drugs
###end article-title 90
###begin article-title 91
###xml 121 125 <span type="species:ncbi:10116">rats</span>
Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats
###end article-title 91
###begin article-title 92
Agonist-receptor efficacy. II. Agonist trafficking of receptor signals
###end article-title 92
###begin article-title 93
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Dual activation by lisuride of central serotonin 5-HT1A and dopamine D2 receptor sites: drug discrimination and receptor binding studies
###end article-title 93
###begin article-title 94
###xml 96 98 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 107 109 107 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors
###end article-title 94
###begin article-title 95
The discriminative stimulus properties of LSD: mechanisms of action
###end article-title 95
###begin article-title 96
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 84 85 84 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves
###end article-title 96
###begin article-title 97
Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites
###end article-title 97
###begin article-title 98
Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa
###end article-title 98
###begin article-title 99
Bromocriptine and lisuride in Parkinson disease
###end article-title 99
###begin article-title 100
###xml 80 86 <span type="species:ncbi:9606">humans</span>
Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans
###end article-title 100
###begin article-title 101
###xml 61 64 <span type="species:ncbi:10116">rat</span>
Dopaminergic stimulation disrupts sensorimotor gating in the rat
###end article-title 101
###begin article-title 102
Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens
###end article-title 102
###begin article-title 103
###xml 59 61 59 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1A</sub>
###xml 131 135 <span type="species:ncbi:10116">rats</span>
Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats
###end article-title 103
###begin article-title 104
###xml 75 79 <span type="species:ncbi:10116">rats</span>
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI
###end article-title 104
###begin article-title 105
Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus
###end article-title 105
###begin article-title 106
###xml 181 186 <span type="species:ncbi:9606">human</span>
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding properties of 14 drugs at 21 native and cloned human receptor subtypes
###end article-title 106
###begin article-title 107
###xml 155 156 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 187 188 187 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and alpha1/alpha2-adrenoceptor
###end article-title 107
###begin article-title 108
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 159 160 159 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes
###end article-title 108
###begin article-title 109
Serotonin receptors
###end article-title 109
###begin article-title 110
Lysergamides of isomeric 2, 4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD)
###end article-title 110
###begin article-title 111
###xml 69 72 <span type="species:ncbi:10116">rat</span>
###xml 128 131 <span type="species:ncbi:10116">rat</span>
Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains
###end article-title 111
###begin article-title 112
Lisuride in parkinsonism
###end article-title 112
###begin article-title 113
###xml 65 66 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists
###end article-title 113
###begin article-title 114
###xml 24 28 <span type="species:ncbi:10116">rats</span>
Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD
###end article-title 114
###begin article-title 115
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens
###end article-title 115
###begin article-title 116
Lisuride in cluster headache
###end article-title 116
###begin article-title 117
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 36 41 <span type="species:ncbi:9606">human</span>
Hallucinogenic drug interactions at human brains 5-HT2 receptor: implications for treating LSD-induced hallucinogenesis
###end article-title 117
###begin article-title 118
###xml 57 59 57 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1C</sub>
Neurochemical evidence that hallucinogenic drugs are 5-HT1C receptor agonists: what next?
###end article-title 118
###begin article-title 119
Lisuride in Parkinson's disease
###end article-title 119
###begin article-title 120
Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence
###end article-title 120
###begin article-title 121
Blockade of the discriminative stimulus effect of DOI by MDL 100, 907 and the 'atypical' antipsychotics, clozapine and risperidone
###end article-title 121
###begin article-title 122
###xml 78 81 <span type="species:ncbi:10116">rat</span>
(1-(2, 5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists
###end article-title 122
###begin article-title 123
###xml 93 97 <span type="species:ncbi:10116">rats</span>
Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats
###end article-title 123
###begin article-title 124
###xml 47 51 <span type="species:ncbi:10116">rats</span>
8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100, 135 and localization of site of action
###end article-title 124
###begin article-title 125
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 97 99 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 56 59 <span type="species:ncbi:10116">rat</span>
DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not by 5-HT2C receptors
###end article-title 125
###begin article-title 126
Migraine prophylaxis with Lisuride hydrogen maleate-a double blind study of Lisuride versus placebo
###end article-title 126
###begin article-title 127
Ein neues, in sehr kleinen mengen wirksames phantastikum
###end article-title 127
###begin article-title 128
###xml 54 55 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
###end article-title 128
###begin article-title 129
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients
###end article-title 129
###begin article-title 130
Drugs five years later. Bromocriptine
###end article-title 130
###begin article-title 131
Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states
###end article-title 131
###begin article-title 132
###xml 18 20 18 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2A</sub>
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2C</sub>
###xml 68 71 <span type="species:ncbi:10116">rat</span>
Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists
###end article-title 132
###begin article-title 133
###xml 51 57 <span type="species:ncbi:9606">humans</span>
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
###end article-title 133
###begin article-title 134
###xml 103 108 <span type="species:ncbi:9606">human</span>
The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval
###end article-title 134
###begin article-title 135
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
###end article-title 135
###begin article-title 136
Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions
###end article-title 136
###begin article-title 137
###xml 77 80 <span type="species:ncbi:10116">rat</span>
Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat
###end article-title 137
###begin article-title 138
###xml 66 69 <span type="species:ncbi:10116">rat</span>
Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies
###end article-title 138
###begin article-title 139
Lack of specificity of an animal behavior model for hallucinogenic drug action
###end article-title 139
###begin article-title 140
###xml 76 80 <span type="species:ncbi:10116">rats</span>
Terguride, a dopamine D(2) partial agonist, as a discriminative stimulus in rats
###end article-title 140

